RNS REACH |14 March 2024
ImmuPharma
PLC
("ImmuPharma" or the
"Company")
IMMUPHARMA AT BIO-EUROPE
SPRING 2024
18-20 March 2024 |
Barcelona
ImmuPharma PLC (LSE:IMM), the
specialist drug discovery and development company, announces
that Tim McCarthy, CEO and Dr Tim Franklin,
COO, will be attending BIO-Europe Spring. The event will be held
between 18-20 March 2024, in
Barcelona.
BIO-Europe Spring is the premier
springtime partnering event, designed to provide biotechnology
companies with the opportunity to present to and connect with
investors together with the global biopharma community.
Commenting on the event, Tim McCarthy, CEO of ImmuPharma
said: "Following on from our recent
announcements, including moving our lead asset P140 for SLE
(Lupuzor™) forward, with our appointed CRO, Simbec-Orion, in
parallel with our CIDP program, we are delighted to have BIO-Europe
as the next key platform in 2024 to present our unique portfolio to
key industry and investment specialists. Our focus will be to
secure partnering opportunities across our programs including our
P140 platform and our earlier stage but highly exciting
anti-infective asset, BioAMB."
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 203 650 3650
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140/SLE (Lupuzor™), P140 "restores" the immune
system back to normal, by enabling tolerogenic antigen presenting
cells to function properly. P140 is
not an immunosuppressant unlike other molecules in
development. P140 is extremely safe, well-tolerated
and patient friendly, and potentially can be self-administered
through a subcutaneous injection, once a month for SLE.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code: 213800VZKGHXC7VUS895.
About BIO-Europe Spring, Barcelona, 2024
Connecting the global biopharma
community to elevate life science partnerships.
BIO-Europe Spring, is the premier
springtime partnering event, bringing together over 3,700 attendees
from 2,000+ companies to engage in 20,000 one-to-one
meetings.
For
more information go to: https://informaconnect.com/bioeurope-spring/
About Reach announcements
Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement
is required to be notified under the AIM Rules for
Companies.